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Introduction 
Cell based therapy can be defined as the implantation of autologous, allogenic 
or xenogenic cells for the replacement of damaged cells or organ functions. Either 
the implanted cells are able to assume this function by themself or they stimulate 
other cells, which then can cause a regeneration of the tissue or organ function. 
Examples are the treatment of diabetes mellitus with insulin- and GLP-1- secret-
ing cells or Parkinson disease with dopamine-secreting cells as well as the implan-
tation of mesenchymal stem cells for regeneration of heart, cartilage or bone tissue 
[1-6].  
The implantation of allogenic (or xenogenic) cells demands a protection against 
host-versus-graft reactions which can be achieved by a suppression of the reci-
pient’s immune system or by an encapsulation of the transplanted scells.  
Promising, for the treatment of many endocrine or degenerative diseases are 
microencapsulated stem cells, for example the CellBead® system developed by the 
CellMed AG (Alzenau, Germany). These cell beads consist of an inner cell con-
taining core which is surrounded by an alginate capsule (Figure 1). Each cell bead 
contains about 2000 to 3000 cells in a non-proliferating state. The diameter of the 
cell containing core bead is about 400 µm and the diameter of the alginate capsule 
between 500 and 600 µm.   
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Figure 1: Light-microscopic image of cell beads.  
 
The allogenic production cell line is based on human mesenchymal stem cells, 
which are transfected with the gene of the catalytic subunit of human telomerase.  
The telomerase activity counteracts the shortening of the telomeres after each cell 
cycle, that means a transformation of the cells to a permanent cell line [7]. Depen-
dent on the designated use the cells are genetically modified with additional thera-
peutic genes.  
The cell beads can be implanted by injection using a sterile syringe. At the im-
plantation place the cells are provided with nutrients by diffusion through the cap-
sule and in turn release therapeutic molecules. Antigens and components of the 
host immune system cannot penetrate through the capsule (Figure 2). The advan-
tages of this therapeutical system are a continuous drug delivery and due to the lo-
cal application high drug concentrations at the point of implantation. Furthermore, 
a production in stock is possible since a cell line is used.  
 
 
   
 
Figure 2: The alginate capsule of a cell bead acts as a semipermeable membrane. 
 
The implantion of this cell therapeutic system behind the blood-brain barrier 
makes them suitable for the treatment of e.g. stroke. Clinical phase 1 studies with 
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GLP-1-transfected cells revealed a reduced loss of neuronal cells in a controlled 
cortical impact rat model due to the implantation of GLP-1 secreting cell beads 
[8]. Originally, intestinal cells secret GLP-1in reply to food intake. GLP-1 en-
hances insulin secretion of beta-cells as well as promoting insulin sensitivity. 
Since GLP-1 receptors are also expressed throughout the mammalian brain, the 
implantation of GLP-1 secreting cell beads into the brain may cause neurotrophic 
and neuroprotective effects. 
 
The production process of cell based implants consists of  three steps, whereas this 
article is focused on the first and third production steps (Figure 3).  
 
 
 
 
Figure 3: Steps and requirements of the cell bead production process.  
 
Due to the fact that the cells themselves are the product, the requirements of the 
stem cell expansion process differ from a common mammalian cell culture, where, 
for example, a virus or protein is the product. 
The cultivation and harvesting procedure for the expansion of the stem cell 
based production cell line should be very gentle in order to obtain high yields and 
vitalities of harvested cells. The used carrier should be non-porous which ease the 
separation of detached cells from the carrier. 
The cell bead cultivation process aims to increase the vitality of the encapsu-
lated cells. A decrease of the cell vitality of the implants may be caused by the 
harvesting and encapsulation procedure. Apoptotic cells shall be decomposed dur-
ing this cultivation.  
An optional differentiation of the cell beads may support the cell survival at the 
transplantation place. Furthermore, a differentiation may induce the expression of 
therapeutic molecules. 
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Here we introduce two fixed-bed bioreactor systems, one for the expansion of 
the adherent production cell line and the other for the cultivation of the cell beads. 
As an example the application of an adipogenic differentiation protocol was inves-
tigated.  
Both fixed-bed systems have to be transferred into a GMP-process. Therefore 
some requirements are addressed to the reactor systems. For maintaining sterility 
during the process they have to be designed as a closed system with the possibility 
of online monitoring. Furthermore, an automation of the process should be 
enabled to reduce human error and labor input. A simple design of the reactor sys-
tem and its peripheral components benefit the manufacturing of disposables, 
which reduces extensive cleaning procedures and documentation effort. Figure 3 
gives an overview about the cell bead production process and its requirements. 
Expansion of hMSC-TERT  
Reactor system 
Many disposable reactor systems used in the cultivation of adherent animal 
cells like T-flasks, roller bottles, wave reactors, stirred-tank reactors or spinner 
flasks are established, but they show more or less drawbacks. T-flasks and their 
cognate systems are labor consuming in operation, or intricate in automation. Sus-
pension reactors in combination with microcarrier have the drawback that a spe-
cial system for the separation of the enzymatically detached cells from the carrier 
is necessary. This counteracts a simple design which is demanded for manufactur-
ing as a disposable. Therefore a fixed-bed bioreactor system was developed, 
which is based on non-porous carrier. The advantage of non-porous carrier is that 
the adherent cells, located on the carrier surface, can be easily flushed out of the 
reactor with the medium flow after enzymatic detachment. A carrier screening has 
revealed that non-porous borosilicate glass spheres (BSGS) are most suitable in 
respect to the growth behavior, cell harvest and nutrient supply.  
Figure 4 shows a prototype of the fixed-bed reactor. It consists of a glass cy-
linder with a stainless steel lid and bottom plate, which are equipped with hose 
connectors for the medium inlet and outlet. A funnel shaped insert leads to a near-
ly uniform inflow. The periphery of the fixed bed consists of some flasks that act 
as conditioning, collecting, waste and storage vessel, the tubing, some pinch 
valves, two peristaltic pumps, single use noninvasive oxygen sensors (PreSens - 
Precision Sensing GmbH, Regensburg, Germany) for process monitoring and ste-
rile air filter for pressure adjusting of the vessels. All parts except the valves and 
the pumps can be designed for production as a disposable, or they are already 
available as commercial single use items. A further advantage of this system is a 
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comfortable automation of the process including the inoculation, culturing and 
harvesting procedure.  
The oxygen supply can be provided by a surface aeration or in larger systems 
with a single use membrane oxygenator. Bubble aeration would have the draw-
backs of foam forming when serum containing medium is used. 
The reactor system can be operated in a humidified incubator at 37°C and 5% 
CO2. Larger scales demand special heating strategies for the fixed bed and the 
conditioning vessel. Furthermore, a gas mix station is demanded when the me-
dium is aerated by using membrane oxygenators in order to enrich the feed air 
with CO2, which is necessary for a pH adjustment of sodium bicarbonate buffered 
medium.   
 
 
 
 
Figure 4: Fixed-bed reactor system for the expansion of hMSC-TERT.  
 
For determination of growth and consumption kinetics and for scale up calcula-
tions a mathematical model was used that is shown here in a simplified manner 
(Figure 5). 
 
 
6  
 
Figure 5: Simplified illustration of the mass balances of the fixed-bed reactor and 
its associated conditioning vessel.  
 
The system is mainly composed of the interacting compartments, the fixed bed 
and the conditioning vessel. The concentration c  of any nutrient component in the 
fixed bed depends on time and axial position z  and can be expressed by this con-vection- consumption equation: 
 
( )FB
cv q X t
z
δ η
δ
− ⋅ = ⋅ ⋅
     Equation 1 
 
with the superficial velocity v , which is defined as the flow velocity in the reactor 
tube without the packed bed, the cell specific consumption rate q  of the regarded 
nutrient component, the time dependent and volume specific cell density   
 
0( ) µ tFB FBX t X e
⋅= ⋅      Equation 2 
 
and the effectiveness factor η ,  that considers mass transfer resistance [9-14]. The 
growth rate µ
 
and the glucose consumption rate 
Glcq
 
can be described by Monod 
kinetics: 
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,
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cµ µ
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+      
Equation 3 
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with the Monod constants 
, GlcM q
k and ,M µk  whereas the oxygen consumption rate 
Oxq  is assumed to be concentration independent: 
 
.Oxq const=       Equation 5 
 
For the concentration 
CVc  in the conditioning vessel only time dependence is as-
sumed. It can be described by balancing the nutrient in- and outflow: 
 
CV
CV FB
cV V c V c
t
δ
δ
⋅ = − ⋅ + ⋅ 
    
Equation 6
 
 
with the concentration at the reactor outlet 
FBc , the medium volume V  and the vo-
lume flow V .  In the case of an oxygen balance equation 6  has to be extended by 
the oxygen transfer rate OTR : 
 
,
, ,
CV Ox
CV Ox FB Ox
c
V V c V c OTR
t
δ
δ
⋅ = − ⋅ + ⋅ + 
   Equation 7 
 
Expansion of hMSC-TERT in lab scale 
Fixed-bed cultivations of hMSC-TERT were performed in scales up to a bed 
volume of 300 cm3. With these cultivations several process relevant problems 
could be investigated (Figure 6).   
 
A carrier screening was performed to find a suitable carrier regarding growth 
and harvesting behavior of the hMSC-TERT.  
Inoculation and harvesting procedures were developed, which are automata-
ble and leading to high yields of adhered or detached cells, respectively. Further-
more, the harvesting procedure has to result in a high vitality of the detached cells. 
The lab scale bioreactor system for the cell expansion has to be scaled up to 
the production scale. Therefore a maximal superficial velocity has to be defined, 
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in order to avoid negative effects on the cell growth caused by shear stress. Model 
parameters like growth and consumption rates, which are necessary for scale up 
calculations, were determined by fitting them to the experimental data.  
 
 
 
 
 
Figure 6: Overview of performed lab scale experiments for the development of a 
fixed bed based expansion process for hMSC-TERT.  
Carrier screening 
Non-porous borosilicate glass spheres of 1, 2 and 3 mm diameter as well as 
fibrous macroporous polyethylene terephthalate based carrier (BioNoc IITM, Cesco 
Bioengineering Co, Taichung, Taiwan) were investigated and compared.  
Therefore, reactors were filled with 60 cm3 carrier and inoculated with a cell 
number corresponding to 5000 cells per cm2. During the four hour inoculation 
procedure without perfusion of the fixed bed, the reactors were manually turned 
around 180° after 10, 40, 130 and 240 min in order to return sedimented and non-
attached cells into the fixed bed. After the inoculation procedure, the cultivation 
was started by perfusion of the system with EMEM (Eagle’s Minimal Essential 
Medium) supplemented with 10% fetal calf serum (FCS). Table 1 gives more de-
tail to the cultivations. The final cell numbers at the end of the cultivations were 
determined by counting of crystal violet stained nuclei after lysis of the cells with 
citric acid [15].  
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Table 1: Cultivations of hMSC-TERT in 60 cm3 fixed-bed reactors aimed at find-
ing suitable carrier. 
Carrier 
Sphere  
diameter dS 
[mm] 
Growth surface per 
60 cm3 fixed bed  A 
[cm2] 
Medium 
volume V 
[ml] 
Superficial  
Velocity v 
[m/s] 
BioNoc IITM - 9600 1000 1.5 x 10-4 
Borosilicate 
glass spheres  
1 2196 500 3.0 x 10-4 
2 1098 500 3.0 x 10-4 
3 732 500 3.0 x 10-4 
 
 
The results of the cultivations (Figure 7) are summarized in Table 2. The high-
est growth rate as well as the highest cell density after 160 hours was reached with 
2mm borosilicate glass spheres. The lowest number of attached cells after the in-
oculation procedure was obtained with BioNoc IITM. Channeling was detected by 
using of borosilicate glass spheres with a diameter of 1mm, which means a non-
optimal nutrient supply and thus limitations of the cells.  
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Figure 7: Cultivations of hMSC-TERT in 60cm3 fixed-bed reactors on non-
porous borosilicate glass spheres (BSGS) and macroporous BioNoc IITM carrier. 
Red curves (2 mm  BSGS) were simulated using the model.  BSGS: Borosilicate 
glass spheres 
Table 2: Results of the comparative cultivations of hMSC-TERT in 60 cm3 fixed-bed reactors on different carrier. The mean growth 
rates 
maxµ  and the cell densities FBX  after the inoculation procedures were obtained by fitting of Equation 2 to the experimental data. 
BSGS: Borosilicate glass spheres 
 Units 1 mm BSGS * 2 mm BSGS  3 mm BSGS  BioNoc IITM 
Cultivation time  [h] 192 168 192 168 
Mean growth rate 
maxµ  [1/d] 0.307 ± 0.062  0.487 ± 0.042  0.372 ± 0.063  0.391 ± 0.034 
Cell density at the end of 
cultivation 
FBX  
[1/cm2]  
[1/cm3] 
6.69 x 104            
2.45 x 106 
9.64 x 104           
1.75 x 106 
1.32 x 105           
 1.61 x 106 
1.54 x 104 
5.63 x 105 
Cell density after 160 h 
FBX  
[1/cm2]  
[1/cm3] 
(5.11 ± 2.20) x 104                  
(1.66 ± 0.72) x 105                  
(9.32 ± 2.55) x 104                  
(1.71 ± 0.47) x 105                  
(7.92 ± 3.60) x 104                  
(9.50 ± 4.31) x 105                  
(1.31 ± 0.29) x 104                  
(2.01 ± 0.46) x 105                  
Cell density after the in-
oculation procedure 0
FBX   
[1/cm2] 
[1/cm3] 
(6.58 ± 2.84) x 103                 
(2.14 ± 0.92) x 105                  
(3.68 ± 0.99) x 103                 
(6.63 ± 1.81) x 104                  
(6.63 ± 3.01) x 103                 
(7.96 ± 3.61) x 104                  
(9.68 ± 2.10) x 102  
(1.55 ± 0.34) x 105                 
R2 [-] 0.946 0.998 0.932 0.986 
* channeling  
 
 
 
 
 
 
 
 
 
 
Beside the growth behavior the yield after a harvesting procedure was used for 
an evaluation of the carrier. Therefore fixed beds consisted of 2mm glass spheres 
or BioNoc IITM were cyclic perfused with AccutaseTM or Trypsin solution, respec-
tively, for 20 minutes at a superficial velocity of 1.3 x 10-4 m/s.  
AccutaseTM was more effective regarding the yield of detached cells than Tryp-
sin (Figure 8). The highest yield of 92% was obtained with 2 mm glass spheres 
and AccutaseTM. 
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Figure 8: Preliminary harvesting experiments in fixed-bed reactors containing 
2 mm borosilicate glass spherese or BioNoc IITM, respectively. The beds were cyc-
lic perfused with enzyme solution for 20 minutes. The data represent the mean ± 
standard deviation of four experiments.   
 
Considering the previous facts, borosilicate glass spheres with a diameter of 
2 mm are most suitable for the cultivation and harvesting procedure of hMSC-
TERT. The next steps including the development of automatable inoculation and 
harvesting procedures as well as the determination of kinetic parameters for scale 
up calculations were performed with 2 mm borosilicate glass spheres. 
Inoculation procedure 
The main problem by inoculation of the fixed bed was that non-adherend cells 
sedimented and did not get the chance to adhere to the carrier when the system is 
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filled with cell suspension and incubated without perfusion. This yielded in a 
small amount of adhered cells and an axial cell density profile. Therefore, perfu-
sion steps should be included in the inoculation procedure.  
Figure 9 shows an inoculation procedure with intermittent perfusion intervals. 
The yield, which is defined as the ratio of adherend cells to the inoculated cell 
number could be increased from 30%, without perfusion, to about 50%, with per-
fusion.  
 
Figure 9: Scheme of the inoculation procedure. Repeated perfusion steps enhance 
the number of attached cells and thus the yield of the inoculation procedure.  
Determination of the maximal superficial velocity 
Due to the non-porosity of the glass carrier, the cells are totally exposed to the 
shear stress caused by the medium flow, which requires a definition of a maximal 
superficial velocity. For this purpose, hMSC-TERT were cultured in 25 cm3 fixed 
beds at different superficial velocities. The growth rate was used as an evaluation 
parameter. A reference culture in 6-well cell culture plates was performed to get 
the maximal growth rate at v = 0.  
The growth rate starts to decrease at about 3.0 x 10-4 m/s (Figure 10). This ve-
locity was used for scale up calculations and experimental determinations of 
growth and consumption kinetics in fixed-bed reactors.   
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Figure 10: Growth rates of hMSC-TERT in a fixed bed consisting of non-porous 
borosilicate glass spheres with a diameter of 2 mm at  different superficial veloci-
ties. The data represent the mean ± standard deviation of four cultivations. 
Cultivation in different scales - consumption and growth kinetics 
Cultivations were performed in scales from 15 to 300 cm3. Growth, oxygen 
and glucose consumption kinetics were determined by fitting of the model para-
meters to the experimental data. Glutamine wasn’t considered since it is an unim-
portant energy source for hMSC [16]. The modeled curves for a 60 cm3 scale are 
exemplarily shown in Figure 7. 
Table 3 shows the fitted model parameters. The growth and consumption rates 
are comparable to those reported in the literature. Glucose consumption and 
growth rates of human mesenchymal stem cells are referred to be  (0.23 – 1.22) x 
10-7 mg/h/cell [17, 18] and 0.33 – 0.94 1/d [15, 16, 19-22], respectively. Oxygen 
consumption rates of (1.22 – 3.20) x 10-8 mg/h/cell are reported for various human 
cell types [23-27].   
Most important for scale up considerations is the oxygen consumption rate. 
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Table 3: Consumption and growth kinetics of hMSC-TERT cultured on 2 mm bo-
rosilicate glass spheres in fixed-bed reactors at 15, 60 and 300 cm3  scales. The da-
ta were obtained by fitting the model parameters to the experimental data. 
 
Maximal growth rate 
maxµ  0.55 – 0.69 [1/d] 
Monod constant  
,M µk  0.135 – 0.160 [mg/ml] 
Maximal glucose consumption rate 
,maxGlcq  (8.0 – 11.8)  x 10-8 [mg/h/cell] 
Monod constant 
, GlcM q
k  0.10 – 0.16 [mg/ml] 
Oxygen consumption rate 
Oxq  (0.98 – 2.14) x 10-8 [mg/h/cell] 
 
Harvesting procedure 
A drawback of the used preliminary harvesting procedure for the carrier 
screening was that, due to the cyclic perfusion of the enzyme solution, already de-
tached cell were repeatedly passed through the reactor system. This caused shear 
stress which led to a decrease in vitality to values below 90% (data not shown). 
Therefore, a harvesting procedure was developed at which the cell suspension will 
be directly to the collecting vessel (Figure 11).  
In the first step, cells become detached by perfusion of the fixed bed for 10 
minutes with AccutaseTM solution at a superficial velocity of 1.8 x 10-4 m/s. After 
this the cells get flushed out by perfusion with medium at a superficial velocity of 
3.2 x 10-3 m/s for 2 minutes. This harvesting procedure resulted in a yield of de-
tached and separated cells of approximately 82% and a vitality of about 96%.  
The advantages of this procedure are the comfortable automation and separa-
tion of the detached cells without any further system components or process steps.  
 
 
 
 
 
Figure 11: Harvesting of hMSC-TERT in fixed-bed reactors based on non-porous 
borosilicate glass spheres.  
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Theoretical scale up of the hMSC-TERT expansion process 
For scale up calculations of the fixed bed, mainly the dissolved oxygen con-
centration has to be considered, since it is magnitudes lower than other limiting 
medium components such as glucose. The oxygen concentration or saturation, re-
spectively, decreases in axial direction that demands a definition of a maximal 
fixed-bed height 
FBh  (Figure 12). 
 
 
 
Figure 12: Dependency of the bed height on the outlet oxygen saturation and tar-
get cell density calculated using the model of the cultivation process and the max-
imal oxygen consumption rate (Table 3).  
 
The maximal fixed-bed height depends, assuming an 100% air saturated inflow 
concentration and a constant inflow velocity (3.0 x 10-4 m/s), on the maximal cell 
density and the minimal oxygen concentration in the fixed bed, which can be 
found at the outflow region. This maximal bed height can be calculated by using 
the previously described model: 
 
,( ,  )FB FB Ox outh f X c=      
Equation 8
 
 
Using the maximal bed height, a calculation of the maximal volume 
FBV  of a sin-
gle fixed bed as a function of the thickness ratio TR  and with it a calculation of 
the needed number 
FBn  of parallel operated fixed-bed reactors for the cultivation 
of a certain target cell  number 
XN  is possible:   
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2
FB
FB FB
hV h
TR
π  = ⋅ ⋅ ⋅       
Equation 9 
 
X
FB
FB FB
Nn
X V
=
⋅       
Equation 10 
 
 
The reactor system was scaled exemplarily for the cultivation of a target cell 
number of 20 billion cells that is sufficient for approximately 200 single doses of 
cell beads with a volume of about 5 ml per dose (Table 4). 
The volume of a single fixed bed decreases with increasing cell number, thick-
ness ratio, and outlet oxygen saturation. Small reactor volumes means a large 
number of parallel operated fixed-bed reactors, but this is very intricate and non-
practical regarding the handling and operation of the bioreactor system. Therefore 
a reduction of the target cell density, as well as a reduction of the thickness ratio 
and the outlet oxygen saturation is recommended. As a result of this small num-
bers of parallel operated reactors which can be handled and operated easier are ob-
tained. The oxygen outlet concentration, of course, can only be decreased to an 
uncritical value. 
 
Table 4: Numbers and volumes of parallel operated fixed beds needed for the cul-
tivation of 2 x 1010 cells as a function of thickness ratio, target cell density, and 
outlet oxygen saturation. 
 Thickness ratio = 1  Thickness ratio = 2   
Target cell den-
sity [cm-3]  
Fixed-bed 
volume  
VFB [L]  
Number 
of fixed 
beds  nFB  
Fixed-bed 
volume 
VFB   [L]  
Number 
of fixed 
beds nFB  
Total fixed-
bed volume 
[L]  
Outlet oxygen saturation: 20%  
1  x 106   20  1.1  5.2  4.2  21.9  
2  x 106   2.3  4.8  0.6  19.1  10.9  
4  x 106   0.3  18.3  0.07  73.1  5.5 
Outlet oxygen saturation: 30%  
1  x 106   13.4  1.6  3.4  6.5  21.9  
2  x 106   1.5  7.3  0.4  29.0  10.9  
4  x 106   0.2  27.8  0.05  111.4  5.5 
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Cultivation of encapsulated cells 
The reactor system 
The cell bead cultivation system is based on single use plastic syringes at 
which the cell beads which themself form the bed. The original piston is replaced 
by a custom made insert, which enables the perfusion of the fixed bed (Figure 13).  
Beside the cultivation on a single dose level the advantages of this bioreactor 
system are a cryopreservation of the cell beads by direct freezing of the syringe 
and post-thaw an implantation of the cell beads using this syringe. This avoids 
contamination risky transfer steps. For this purpose, the insert can be designed in a 
manner that it can act as the original syringe piston. 
The reactor periphery is similar to that of the hMSC-TERT expansion system. 
Furthermore the previously described mathematical model can be used as well for 
the simulation of the cell bead cultivation process.  
 
 
 
 
 
 
19 
 
Figure 13: System for the cultivation of cell beads in syringe based fixed reactors.  
Cultivation of encapsulated cells  
Cultivations of cell beads were exemplarily performed under adipogenic con-
ditions in a 1 cm3 scale (data not shown). Induction medium was applied for 3 
days followed by 4 days cultivation with maintenance medium (Table 5). This 
cycle was repeated three times [14]. Medium, 50 ml per cycle, was perfused at a 
superficial velocity of 1.28 x 10-4 m/s that is below the fluidization point. Refer-
ence cultures were performed in 25 cm2 T-flasks using the same protocol. 
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Table 5: Composition of media for the adipogenic cultivation of cell beads [28].   
Induction medium Maintenance medium 
DMEM + 10% FCS DMEM + 10% FCS 
100 U/ml penicillin 100 U/ml penicillin 
0.1 mg/ml streptomycin 0.1 mg/ml streptomycin 
0.01 mg/ml insulin 0.01 mg/ml insulin 
0.5 mM 3-isobutyl-1-methyl-xanthin - 
0.2 mM indomethacin - 
1 μM dexamethason - 
 
 
Vitality was determined after 0, 100, 200, and 500 hours with the Trypan blue 
exclusion method after lysis of the cell beads using EDTA [28].  
The vitality increased with advancing cultivation time, whereas the cell num-
ber decreased (Figure 14). This is explainable by a decomposition of apoptotic 
cells. Apoptosis may be triggered by the harvesting or the encapsulation process, 
or dominant in this case, by the cryopreservation of the cell beads prior to the cul-
tivation. It could be shown that the vitality, and thus the quality of the beads is 
gradable during the cultivation process.   
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Figure 14: Time dependent vitality and cell number of cell beads cultured in 
fixed-bed reactors and in T-flasks (reference).  
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As example an adipogenic differentiation protocol was applied, whereby the 
differentiation to adipocytes was verified by staining with the lipophilic fluores-
cence dye Nile red (Figure 15) [28]. Adipogenic cultured cell beads showed high-
er fluorescence intensity and thus are interpreted to be diffentiated to adipocytes. 
No differences between the fixed-bed culture and the reference culture in T-flasks 
are detectable. 
Table 5 shows the kinetics obtained by fitting of the model parameter to the 
experimental data which were used for a theoretical scale up of the system.  
 
 
 
 
Figure 15: Nile red staining of cell beads which were cultured under adipogenic 
and non-adipogenic conditions in fixed-bed reactors or T25-flasks. 
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Table 6: Consumption kinetics of encapsulated hMSC-TERT (cell beads) which 
were obtained by fitting of model parameters to the experimental data of the adi-
pogenic cultivation in a 1 cm3 fixed-bed scale (Figure 14).  
Growth rate 
maxµ  0 [1/d] 
Maximal glucose consumption rate 
,maxGlcq  (7.3 – 9.4)  x 10-8 [mg/h/cell] 
Monod constant 
, GlcM q
k  0.06 [mg/ml] 
Oxygen consumption rate 
Oxq  5.5 x 10-9 [mg/h/cell] 
Theoretical scale up of the cell bead cultivation process 
A calculational scale up was carried out for a cultivation of 200 single doses of 
cell beads of each 5 ml (Figure 16). The inlet oxygen concentration was assumed 
to be air saturated. This can be realized, for example, by using membrane oxyge-
nators.   
For a calculation of the oxygen or glucose concentration profile in the cell 
bead, the following diffusion and diffusion-reaction equations were used:  
 
2
2
2CC CC
CC CC
d c dcD q X
dr r dr
 
⋅ + ⋅ = ⋅ 
      
Equation 11 
 
2
2
2 0AC ACAC
d c dcD
dr r dr
 
⋅ + ⋅ = 
      
Equation 12 
 
with the concentration in the cell containing core bead 
CCc  as well as in the cell 
free alginate capsule 
ACc , the effective diffusion coefficient in the core bead CCD
and alginate capsule 
ACD  and the cell density of the core bead CCX .  
It could be shown that an oxygen saturation in the medium of 40 % leads to a 
oxygen saturation at the center of approximately 22 % (Figure 16). The difference 
of glucose between the medium and the cell bead center is negligible. Thus, it can 
be assumed that no limitations of the cells at the center of a cell bead are expecta-
ble.  
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Figure 16: Simulated adipogenic cultivation of 200 single doses (5 cm3) of cell 
beads as well as the glucose and oxygen profile at the cell bead center.  Medium 
volume per cycle: 40 L, superficial velocity: 2.5 x 10-4 m/s 
 
Conclusion and Outlook 
Two fixed-bed reactor systems for the production of stem cell based therapeutic 
implants were introduced. One system was developed for the expansion of the 
production cell line (hMSC-TERT) and a second for the cultivation of encapsu-
lated cells in order to increase their vitality and thus the quality of the implants.  
The fixed-bed system for the expansion of the production cell line is based on 
non-porous borosilicate glass spheres. Cells can be cultured and harvested with 
high yield and vitality. The separation of the cells from the carrier can be easily 
performed by flushing them out with the medium flow. This saves additional 
process steps. 
The fixed-bed system for the cultivation of encapsulated cells is based on 
commercial available syringes in which the cell beads represent the bed. The ad-
vantage of this system is that it can be used as implantation tool after the cultiva-
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tion procedure. It could be shown that the vitality is gradable by the cultivation 
process. Furthermore, the application of an adipogenic differentiation protocol 
could be demonstrated.   
Both systems can be automated and produced as disposable items due to their 
simple design. 
The next steps will concern the development of a GMP-conform cryopreserva-
tion procedure for the cell beads and the implementation of the cultivation systems 
to the overall GMP-process of cell bead production.  
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